Chime Biologics congratulates Hope Medicine on HMI-115's CDE Breakthrough Therapy Designation

October 24, 2024/in Corporate News, News/by chi9iua

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event

September 30, 2024/in Corporate News, News/by chi9iua

A Brief introduction on the Challenges and Strategies in Antibody Drug Production

September 18, 2024/in Corporate News, Science & Technology/by chi9iua

pilot-plant-of-chime-biologics

August 14, 2024/in Corporate News, News/by chi9iua

Going Global - Chime Biologics Embraces Innovation and Quality with Partners

June 18, 2024/in Corporate News, News/by chi9iua

(中文) 生物类似药中美欧法规速递

May 23, 2024/in Corporate News, NewsRoom, Science & Technology/by chi9iua

Sorry, this entry is only available in 中文. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

Whitepaper | Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

April 19, 2024/in Corporate News, Uncategorized, Whitepapers/by chi9iua

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

March 12, 2024/1 Comment/in Corporate News, News/by Qiqi Zhang

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

September 28, 2023/1 Comment/in Corporate News, News/by Qiqi Zhang

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch

September 20, 2023/in Corporate News, News/by Qiqi Zhang

Chime Biologics congratulates Hope Medicine on HMI-115's CDE Breakthrough Therapy Designation

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event

A Brief introduction on the Challenges and Strategies in Antibody Drug Production

pilot-plant-of-chime-biologics

Going Global - Chime Biologics Embraces Innovation and Quality with Partners

(中文) 生物类似药中美欧法规速递

Whitepaper | Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch

ABOUT US

Our Services

CONTACT US